Acceleron Pharma (XLRN) Stock Price, News & Analysis

Acceleron Pharma Inc. (NASDAQ:XLRN) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.18. The biopharmaceutical company had revenue of $34.20 million for the quarter, compared to analysts' expectations of $35.39 million. Acceleron Pharma had a negative net margin of 226.01% and a negative trailing twelve-month return on equity of 32.11%. Acceleron Pharma's quarterly revenue was up 51.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.66) earnings per share.

11 employees have rated Acceleron Pharma Chief Executive Officer Habib Dable on Glassdoor.com. Habib Dable has an approval rating of 100% among the company's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN).